|Mr. Steven A. Kriegsman||Chairman, CEO & Pres||1.01M||N/A||75|
|Mr. John Y. Caloz||CFO, Chief Accounting Officer & Treasurer||535k||N/A||65|
|Mr. David J. Haen||VP of Bus. Devel. & Investor Relations||N/A||N/A||39|
|Dr. Shanta Chawla M.D.||Sr. VP of Drug Devel.||N/A||N/A||N/A|
|Dr. Bruce Spiegelman Ph.D.||Member of Scientific Advisory Board of CytRx Laboratories Inc||N/A||N/A||N/A|
CytRx Corporation operates as a biopharmaceutical research and development company specializing in oncology. The companys product candidate is the aldoxorubicin, which is in Phase III clinical trial as a therapy for patients with soft tissue sarcomas (STS) whose tumors have progressed following treatment with chemotherapy; in Phase IIb clinical trial in small cell lung cancer; in Phase II clinical trial in HIV-related Kaposi's sarcoma; in Phase II clinical trial in patients with late-stage glioblastoma (brain cancer); in Phase Ib trial in combination with ifosfamide in patients with STS; and in Phase Ib trial in combination with gemcitabine in subjects with metastatic solid tumors. It also has completed Phase IIb and Phase Ib/II clinical trials with aldoxorubicin as a first-line therapy for STS; a Phase Ib clinical trial of aldoxorubicin in combination with doxorubicin in patients with advanced solid tumors; and a Phase Ib pharmacokinetics clinical trial in patients with metastatic solid tumors. The company is also developing anti-cancer drug conjugates, which utilizes its Linker Activated Drug Release technology. CytRx Corporation was founded in 1985 and is headquartered in Los Angeles, California.
CytRx Corporation’s ISS Governance QualityScore as of July 1, 2017 is 10. The pillar scores are Audit: 10; Board: 7; Shareholder Rights: 10; Compensation: 10.